NTBL - Notable Labs Ltd Analyst Forecast Prices

Notable Labs, Ltd. (NTBL) is developing a precision medicine system for the therapy of hematological tumors by selecting optimal drugs through the analysis of a patient's live cells. The company is currently in an expansion phase, offering pharmaceutical companies services to predict the body's reaction to medications. Historical price action, where the indicator equals 9.03, confirms its status as an innovator with the unique Notable platform, which allows for the laboratory testing of hundreds of treatment options.

notablelabs.com - NTBL Price Target Chart (period 02/21/2024 - 11/02/2024)

Analytical breakdowns for Notable Labs Inc. (NTBL)

- stock price and consensus target price:
Share Price notablelabs.com|NTBL - Consensus Target
- market capitalization statistics:
Market Value Notable Labs Inc.|NTBL - Enterprise Value
- book capitalization information:
Net Assets per Single Share Notable Labs|NTBL - Company Book Value|Market Value to Book Value Ratio notablelabs.com|NTBL - Company Total Assets
- debt obligations and liquidity statistics:
Total Debt to Equity Ratio Notable Labs, Ltd.|NTBL - Long-Term Debt to Capital|Short-Term Debt to Capital Notable Labs Corp|NTBL - Company Debts|Debt to Book Value Ratio Notable Labs Inc.|NTBL - Company Long-Term Debts|Company Current Liabilities Notable Labs|Immediate Liquidity notablelabs.com
- financial results and valuation multiples details:
NTBL - Company Net Income|Expected Net Income Notable Labs, Ltd.|NTBL - Price to Earnings Ratio|Future Price to Earnings Multiple Notable Labs Ltd|NTBL - PEG Multiple|Enterprise Value to EBITDA Ratio Notable Labs Inc.|NTBL - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Notable Labs|NTBL - Earnings per share for the last twelve months|Year-over-year earnings per one share growth for the last 12 months notablelabs.com|NTBL - Earnings growth in current year|Expected net earnings per share growth next year Notable Labs, Ltd.
Fundamental company analysis:notablelabs.com (NTBL)

The uniqueness of the Notable Labs, Ltd. (NTBL) IT platform for oncology therapy forecasting partially offsets the binary risks associated with early-stage development. The volume-weighted target, reflected through the consensus target price, filters out market noise, providing investors with an objective vector for the asset's fundamental revaluation based on daily analysis of expert expectations and the real potential of the diagnostic technology.

Competing companies

beigene.com - Broker Consensus Forecast|Halozyme - Consensus Target|Analyst Forecast Prices RVMD (Revolution Medicines Inc)|Ascentage - Analyst Consensus Forecast|CGON: Price Target Chart|UroGen Pharma Ltd. (URGN) - Price Target Chart|BCAX (bicara.com) - Price Target Chart|PSNL (Personalis) - Analyst Consensus Forecast|Consensus Target Erasca Inc (ERAS)|Analyst Consensus Forecast DCTH|Analyst Consensus Forecast Y-mAbs Corp (YMAB)|Price Target Chart Aura Biosciences, Inc. AURA|CADL: Broker Consensus Forecast|Accuray - Analyst Consensus Forecast|SELLAS Life Sciences (SLS) - Consensus Target|ACTU: Analyst Consensus Forecast|Average Forecast Price Citius Oncology Inc (CTOR)|Price Target Chart TuHURA Biosciences Inc.|TARA: Fair Value Consensus|Consensus Target FATE (Fate Therapeutics)|WHWK (aadibio.com) - Fair Value Consensus|Analyst Consensus Forecast TCRX (TScan Therapeutics, Inc.)|CSBR - Consensus Target|XBIT: Consensus Target|CVM - Analyst Consensus Forecast|OS Therapies (OSTX) - Price Target Chart|Radiopharm Theranostics Ltd - Fair Value Consensus|ARTV (Artiva Biotherapeutics Inc.) - Analyst Consensus Forecast|Average Forecast Price Adlai Nortye Limited ANL|Price Target Chart Veru Inc. (VERU)|tempesttx.com - Broker Consensus Forecast|Price Target Chart Xilio Therapeutics XLO|Renovaro Biosciences (RENB) - Average Forecast Price|MURA: Consensus Target|Kairos Pharma Ltd - Analyst Forecast Prices|OKUR: Analyst Consensus Forecast|CytoMed Therapeutics Limited (GDTC) - Analyst Consensus Forecast|CRIS (Curis Inc.) - Analyst Consensus Forecast|Price Target Chart APLM|Price Target Chart Tharimmune Corp (THAR)|Price Target Chart ADVB (advanbiomed.com)|Analyst Consensus Forecast GNPX (Genprex, Inc.)|Calidi Biotherapeutics Inc. (CLDI) - Average Forecast Price|SBFM: Consensus Target|Fair Value Consensus XBIO (Xenetic Biosciences)|Salarius (SLRX) - Price Target Chart|PPBT (Kitov Pharma) - Price Target Chart|AONC (American Oncology Network Inc) - Analyst Consensus Forecast|Analyst Consensus Forecast beigene.com|Analyst Consensus Forecast CKPT|Price Target Chart ELEV (Elevation Oncology Inc.)|Price Target Chart iCAD ICAD|Analyst Median Target Ikena Oncology Inc. (IKNA)|VIRX: Consensus Target|Fair Value Consensus MOR (morphosys.com)|NAYA Biosciences Inc. (NAYA) - Price Target Chart|AAPGV (Ascentage Pharma Group International) - Price Target Chart